BackMilestone Pharmaceuticals Overview

Milestone Pharmaceuticals Total Liabilities

Milestone Pharmaceuticals's total liabilities is $170M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$168.91M
↑ 151.17% YoYΔ $101.66M vs prior year quarter

Peer trimmed avg / median

Loading

Milestone Pharmaceuticals Total Liabilities History

Loading

Milestone Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

Milestone Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Milestone Pharmaceuticals (MIST) FAQ

Milestone Pharmaceuticals (MIST) currently reports a total liabilities of $170M as of September 2026. That compares with $67M in the prior-year period — up 151.2% year over year. Use the charts on this page to explore Milestone Pharmaceuticals's total liabilities history and peer comparisons.

Milestone Pharmaceuticals's total liabilities increased from $67M to $170M — a 151.2% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Milestone Pharmaceuticals reported $170M in total liabilities as of September 2026. That compares with $67M in the prior-year period — up 151.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $170M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Milestone Pharmaceuticals, and consider following MIST for alerts when major investors trade the stock.

Milestone Pharmaceuticals is classified in the Healthcare sector. On total liabilities, it currently shows $170M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MIST with unrelated industries.